PRODUCT TYPES – Page 6

Cell viability failure during tech transfer: regulatory risk assessment and CAPA

The first step in addressing cell viability failures is to recognize the symptoms or signals that indicate an issue. Common signals may include:Click to read the full article.

API microbial limit failure during commercial scale manufacture: data integrity and chromatographic audit trail review steps

Identifying symptoms or signals of microbial limit failure is the first step in addressing potential issues in API manufacturing. Common signals observed during production or lab analysis include:Click to read…

Chain of identity breach during scale-up: patient safety impact and disposition

Detecting a chain of identity breach is often initiated by identifying unusual symptoms or signals on the production floor or within the laboratory environment. These could manifest in various forms,…

API nitrosamine risk exceedance during commercial scale manufacture: GMP investigation checklist and batch disposition evidence pack

Identifying the symptoms or signals that indicate a potential nitrosamine risk during API manufacture is crucial. These signals often arise from various stages of the manufacturing process. Potential symptoms may…

Chain of identity breach during ATMP manufacturing: inspection-ready investigation package

Recognizing symptoms of a potential chain of identity breach is the first step in your investigation. Symptoms may manifest as discrepancies in documentation, unexpected changes in product characteristics, or reports…

API flow property failure after re-crystallization parameter adjustment: how to justify reprocessing vs rejection to FDA/EMA inspectors

The first step in investigating API flow property failures is to identify the symptoms observed in production or analysis. Common signals may include:Click to read the full article.

Chain of identity breach during tech transfer: regulatory risk assessment and CAPA

Recognizing symptoms of a Chain of Identity breach during a tech transfer is crucial for early intervention. Potential signs include:Click to read the full article.

API impurity profile OOS after re-crystallization parameter adjustment: how to justify reprocessing vs rejection to FDA/EMA inspectors

The initial alert to a deviation in the API impurity profile usually arises from routine quality control testing or batch release protocols. Symptoms that signal potential OOS results may include:Click…

Cell viability failure during FDA inspection readiness: patient safety impact and disposition

During routine quality control testing or an internal audit, symptoms signifying a potential cell viability failure may manifest as:Click to read the full article.

API nitrosamine risk exceedance during tech transfer to a new site: control strategy updates for CPPs/CMAs and continued process verification

Identifying the initial symptoms or signals of potential nitrosamine risk exceedance is critical for initiating an effective deviation investigation. Symptoms can manifest at various points in the production and testing…

Vector potency drift during FDA inspection readiness: inspection-ready investigation package

Identifying symptoms of vector potency drift is the initial step in addressing the issue effectively. These symptoms may manifest as:Click to read the full article.

API residual palladium OOS during process validation campaign: how to write a defensible deviation narrative for inspections

Recognizing the early symptoms or signals of an OOS result related to residual palladium is crucial. Common indicators include:Click to read the full article.